Katina Dorton

Katina Dorton joined the Fulcrum Board of Directors in January 2020 and serves as the Chair of the Audit Committee. She currently serves as Chief Financial Officer of Nodthera, a company developing medicines to inhibit the NLRP3 inflammasome. She also serves on the Board of Directors of TScan Therapeutics and US Ecology (Nasdaq: ECOL) and previously served on the Board of Pandion Therapeutics (Nasdaq: PAND) until its acquisition by Merck in 2021. Katina has held CFO positions at several biotechnology companies, including Repare Therapeutics, a synthetic lethality and DNA repair-focused oncology company, AVROBIO, a lentiviral gene therapy company, and Immatics GmbH. Earlier in her career, Katina served as a managing director in investment banking for Morgan Stanley and Needham & Company and as an attorney at Sullivan & Cromwell. Katina received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University, and her B.A. from Duke University.